Datasheet: MCA1038APC

Description:	RAT ANTI DOG CD4:APC
Specificity:	CD4
Format:	APC
Product Type:	Monoclonal Antibody
Clone:	YKIX302.9
Isotype:	IgG2a
Quantity:	100 TESTS

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/10

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species

Dog

Product Form

Purified IgG conjugated to Allophycocyanin (APC) - lyophilized

Reconstitution

Reconstitute with 1.0 ml distilled water

Max Ex/Em

Fluorophore	Excitation Max (nm)	Emission Max (nm)
APC	650	661

Preparation

Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.09% sodium azide (NaN_3)
1% bovine serum albumin
5% sucrose

Immunogen	Canine concanavilin A activated T cell blasts.
External Database Links	**UniProt:** P33705 Related reagents **Entrez Gene:** 403931 CD4 Related reagents
RRID	AB_10843309
Fusion Partners	Spleen cells from immunized DA rats were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.
Specificity	**Rat anti Dog CD4 antibody, clone YKIX302.9**, is a monoclonal antibody specific for the canine CD4 cell surface antigen. Clone YKIX302.9 was clustered at the first Canine Leukocyte Antigen Workshop (CLAW) [Cobbold *et al.* 1992] along with clone CA13.1E4. Rat anti Dog CD4 antibody, clone YKIX302.9 partially depletes circulating T lymphocytes when administered *in vivo*, but alone is not sufficient to prolong allograft survival in a canine transplant model (Watson *et al.* 1993). Uniquely amongst mammals, canine CD4 is expressed by neutrophils as well as by lymphocyte subsets (Moore *et al.* 1992).
Flow Cytometry	Use 10ul of the suggested working dilution to label 10^6 cells or 100ul whole blood
References	1. Watson, C.J. *et al.* (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog. Br J Surg. 80 (11): 1389-92. 2. Gorman, S.D. *et al.* (1994) Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens. Tissue Antigens. 43 (3): 184-8. 3. Out, T.A. *et al.* (2002) Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs. Immunology. 105: 499-508. 4. Benyacoub, J. *et al.* (2003) Supplementation of food with *Enterococcus faecium* (SF68) stimulates immune functions in young dogs. J Nutr. 133: 1158-62. 5. Bauer. T.R. Jr. *et al.* (2006) Correction of the disease phenotype in canine leukocyte adhesion deficiency using *ex vivo* hematopoietic stem cell gene therapy. Blood. 108: 3313-20. 6. Reis, A.B. *et al.* (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by *Leishmania chagasi*. Clin Exp Immunol. 146: 303-11. 7. Miranda, S. *et al.* (2007) Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol. Vet Parasitol. 144 (3-4): 251-60. 8. Yasuda, N. *et al.* (2008) CC chemokine receptor 4-positive CD4(+) lymphocytes in peripheral blood increases during maturation in healthy beagles. J Vet Med Sci. 70 (9): 989-92. 9. Papadogiannakis, E.I. *et al.* (2009) Determination of intracellular cytokines IFN-gamma

and IL-4 in canine T lymphocytes by flow cytometry following whole-blood culture. Can J Vet Res. 73 (2): 137-43.
10. Estrela-Lima, A. *et al.* (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer. 10: 256.
11. Boggiatto, P.M. *et al.* (2010) Immunologic indicators of clinical progression during canine *Leishmania infantum* infection. Clin Vaccine Immunol. 17: 267-73.
12. Tominaga, M. *et al.* (2010) Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma. J Vet Diagn Invest. 22: 438-41.
13. Bund, D. *et al.* (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies. Cell Immunol. 263: 88-98.
14. Pinheiro, D. (2011) Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog. Immunology. 132: 111-22.
15. Araújo, M.S. *et al.* (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. Vet Immunol Immunopathol. 141: 64-75.
16. Mitchell, L. *et al.* (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. Vet Immunol Immunopathol. 145 (3-4): 597-603.
17. Mitchell, L. *et al.* (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 26: 355-62.
18. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. BMC Vet Res. 9: 94.
19. Michael HT *et al.* (2013) Isolation and characterization of canine natural killer cells. Vet Immunol Immunopathol. 155 (3): 211-7.
20. Figueiredo, M.M. *et al.* (2014) Expression of Regulatory T Cells in Jejunum, Colon, and Cervical and Mesenteric Lymph Nodes of Dogs Naturally Infected with *Leishmania infantum*. Infect Immun. 82: 3704-12.
21. Aresu, L. *et al.* (2014) VEGF and MMP-9: biomarkers for canine lymphoma. Vet Comp Oncol. 12: 29-36.
22. Duz AL *et al.* (2014) The TcI and TcII *Trypanosoma cruzi* experimental infections induce distinct immune responses and cardiac fibrosis in dogs. Mem Inst Oswaldo Cruz. 109 (8): 1005-13.
23. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. Vet Immunol Immunopathol. 159 (1-2): 91-6.
24. Yamaya, Y. & Watari, T. (2015) Increased proportions of CCR4(+) cells among peripheral blood CD4(+) cells and serum levels of allergen-specific IgE antibody in canine chronic rhinitis and bronchitis. J Vet Med Sci. 77 (4): 421-5.
25. Miller, J. *et al.* (2015) Humoral and Cellular Immune Response in Canine Hypothyroidism. J Comp Pathol. 153 (1): 28-37.
26. Viana, K.F. *et al.* (2015) Setting the proportion of CD4+ and CD8+ T-cells co-cultured with canine macrophages infected with *Leishmania chagasi*. Vet Parasitol. 211 (3-4): 124-32.
27. Costa-Pereira, C. *et al.* (2015) One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis. BMC Vet Res. 11 (1): 92.
28. Hauck, V. *et al.* (2016) Increased numbers of FoxP3-expressing CD4(+) CD25(+)

regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity. Vet Dermatol. 27 (1): 26-e9.
29. Riondato, F. *et al*. (2016) Analytical and diagnostic validation of a flow cytometric strategy to quantify blood and marrow infiltration in dogs with large B-cell lymphoma. Cytometry B Clin Cytom. 90 (6): 525-30.
30. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. Immunobiology. 221 (1): 12-22.
31. Viana, K.F. *et al.* (2016) Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-). Parasit Vectors. 9: 250.
32. Munhoz.T.D. *et al.* (2016) Regulatory T cells in dogs with multicentric lymphoma: peripheral blood quantification at diagnosis and after initial stage chemotherapy. Arq. Bras. Med. Vet. Zootec. 68 (1): 1-9.
33. Tagawa, M. *et al.* (2016) Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma. PLoS One. 11 (2): e0150030.
34. Schaut, R.G. *et al.* (2016) Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis. J Immunol. 196 (10): 4100-9.
35. Schaut, R.G. *et al.* (2016) Recovery of antigen-specific T cell responses from dogs infected with *Leishmania (L.) infantum* by use of vaccine associated TLR-agonist adjuvant. Vaccine. 34 (44): 5225-34.
36. Deravi, N. *et al.* (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes. Vet Immunol Immunopathol. 191: 5-13.
37. Bahamondes, F. *et al.* (2017) Omental adipose tissue is a more suitable source of canine Mesenchymal stem cells. BMC Vet Res. 13 (1): 166.
38. Roatt, B.M. *et al.* (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. Front Immunol. 8: 217.
39. Anai, L.A. *et al.* (2017) Quantification of Treg cells in peripheral blood and lymph nodes of dogs with multicentric lymphoma Arq Bras Med Vet Zootec. 69 (6): 1496-502.
40. Pellin, M.A. *et al.* (2017) Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study. Vet Comp Oncol. 15 (3): 919-31.
41. Martins, G.C. *et al.* (2018) Clinical-pathological and immunological biomarkers in dogs with atopic dermatitis. Vet Immunol Immunopathol. 205: 58-64.
42. Withers, S.S. *et al.* (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol. 87: 64-74.
43. DeClue, A.E. *et al.* (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy. BMC Vet Res. 14 (1): 119.
44. DaSilva, A.V.A. *et al.* (2018) Morphophysiological changes in the splenic extracellular matrix of *Leishmania infantum*-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens. PLoS Negl Trop Dis. 12 (4): e0006445.
45. Lisiecka. U. *et al.* (2019) Evaluation of T regulatory lymphocytes and serum concentration of selected cytokines in dogs with perianal tumors. Vet Immunol Immunopathol. 207: 10-17.

46. Akiyama, S. *et al.* (2019) Th17 cells increase during maturation in peripheral blood of healthy dogs. Vet Immunol Immunopathol. 209: 17-21.
47. Martini, V. *et al.* (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. Res Vet Sci. 125: 130-5.
48. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis. Vaccines (Basel). 8 (4): 690.
49. Wolf-Ringwall, A. *et al.* (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. Vet Comp Oncol. 18 (3): 342-52.
50. Sayag, D. *et al.* (2020) Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma. Vet Clin Pathol. 49 (3): 476-83.
51. Lee, J. *et al.* (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor. Biomed Res Int. 2021: 6690704.
52. Grudzien, M. *et al.* (2021) A newly established canine NK-type cell line and its cytotoxic properties. Vet Comp Oncol. 19 (3): 567-77.
53. Lee, S.H. *et al.* (2021) Safety and immunological effects of recombinant canine IL-15 in dogs. Cytokine. 148: 155599.
54. Knebel, A. *et al.* (2021) Measurement of canine Th17 cells by flow cytometry. Vet Immunol Immunopathol. 243: 110366.
55. Konno, H. *et al.* (2022) An experimental challenge model for *Leishmania donovani* in beagle dogs, showing a similar pattern of parasite burden in the peripheral blood and liver. Parasitol Res. 121 (12): 3569-79.
56. Kanei, T. *et al.* (2022) Expression and functional analysis of chemokine receptor 7 in canine lymphoma cell lines. J Vet Med Sci. 84 (1): 25-30.
57. do Prado Duzanski, A. *et al.* (2022) Cell-mediated immunity and expression of MHC class I and class II molecules in dogs naturally infected by canine transmissible venereal tumor: Is there complete spontaneous regression outside the experimental CTVT? Res Vet Sci. 145: 193-204.
58. Karayannopoulou, M. *et al.* (2022) Effect of major versus minor mastectomy on host immunity in canine mammary cancer Vet Immunol Immunopathol. Feb 24: 110403.
59. Bragato, J.P. *et al.* (2022) miRNA-21 regulates CD69 and IL-10 expression in canine leishmaniasis. PLoS One. 17 (3): e0265192.
60. Riccardo, F. *et al.* (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. J Immunother Cancer. 10(5):e004007.
61. Matralis, D.T. *et al.* (2023) Intracellular IFN-γ and IL-4 levels of CD4 + and CD8 + T cells in the peripheral blood of naturally infected (*Leishmania infantum*) symptomatic dogs before and following a 4-week treatment with miltefosine and allopurinol: a double-blinded, controlled and cross-sectional study. Acta Vet Scand. 65 (1): 2.
62. Hamouzová, P. *et al.* (2023) Lymphocyte immunophenotyping in dogs with lymphopenia of common causes. Vet Immunol Immunopathol. 261: 110620.
63. Tarone, L. *et al.* (2023) A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma. Mol Ther. 31 (8): 2342-59.

64. Yamauchi, A. *et al.* (2023) Negative Influence of Aging on Differentiation and Proliferation of CD8(+) T-Cells in Dogs. Vet Sci. 10 (9): 541.
65. Bencze, M. *et al.* (2023) Receptor interacting protein kinase-3 mediates both myopathy and cardiomyopathy in preclinical animal models of Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. Nov 01 [Epub ahead of print].
66. Martini, V. *et al.* (2018) A retrospective study of flow cytometric characterization of suspected extranodal lymphomas in dogs. J Vet Diagn Invest. 30 (6): 830-6.
67. DeClue, A.E. *et al.* (2020) Transportation and Routine Veterinary Interventions Alter Immune Function in the Dog. Top Companion Anim Med. 39: 100408.
68. Lee, G.W. *et al.* (2021) Case Report: Long-Term Survival of a Dog With Chronic Lymphocytic Leukemia Treated With Chlorambucil, Prednisolone, and Imatinib. Front Vet Sci. 8: 625527.
69. Sainz, Á. *et al.* (2021) Effect of chemically modified tetracycline-8 (CMT-8) on hematology, blood chemistry, cytokines and peripheral blood lymphocyte subsets of healthy dogs. Res Vet Sci. 136: 200-8.
70. Kang, S.J. *et al.* (2023) Immunomodulatory effects of canine mesenchymal stem cells in an experimental atopic dermatitis model. Front Vet Sci. 10: 1201382.
71. Sheng, R. *et al.* (2023) Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy. Vet Comp Oncol. 21 (1): 28-35.
72. Miguelena Chamorro, B. *et al.* (2023) Characterization of Canine Peyer's Patches by Multidimensional Analysis: Insights from Immunofluorescence, Flow Cytometry, and Single-Cell RNA Sequencing. Immunohorizons. 7 (11): 788-805.

Storage	Prior to reconstitution store at +4°C. Following reconstitution store at +4°C. DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #20487 available at: https://www.bio-rad-antibodies.com/SDS/MCA1038APC 20487
Regulatory	For research purposes only

Related Products

Recommended Negative Controls

RAT IgG2a NEGATIVE CONTROL:APC (MCA6005APC)

North & South America Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com
Worldwide Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com
Europe Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M419650:230616'

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint